Enzymotec is an Israeli based biotech company is developing and manufacturing bio-functional ingredients for the dietary supplements, launches L-?-glycerophosphrylcholine for neurological disorders.

Also known as alpha-GPC or choline alphoscerate, L-?-glycerophosphrylcholine has been used for some time as a dietary supplement aiming to improve mental performance. It serves as a precursor for reconstituting nerve cell membrane component.

Clinical trials over the past two decades have demonstrated that providing choline as GPC to patients with adult-onset dementia disorders favour memory and attention. The clinical efficacy of GPC (1,000-1,200 mg/d) has been associated in these studies with protection against cognitive impairment characteristics of dementia disorders.

The new launch of GPC is a part of Enzymotec's overall strategy to offer a full line of cognitive solutions aimed to different age groups, mental capacity and price. The company recently launched the SharpPS gold grade, which provides a PS-DHA conjugate, capable of enhancing PS's cognitive effect, through its unique combination with DHA.

Enzymotec's product are: SharpPS - phosphatidylserine for brain improvement, InFat - structured fat for infant formulas, which mimics mother's milk capacity to increase Calcium and energy intake and CardiaBeat - for reducing several CVD-risk factors simultaneously.